ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2379

A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy
Abstract Number: 2380

Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Abstract Number: 2381

ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Abstract Number: 2382

Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Abstract Number: 2383

Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience
Abstract Number: 2384

Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group
Abstract Number: 2385

Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Abstract Number: 2386

Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Abstract Number: 2387

Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study
Abstract Number: 2388

Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study
Abstract Number: 2389

Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Abstract Number: 2390

Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6
Abstract Number: 2391

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register
Abstract Number: 2392

Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 2393

CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].